Navigation Links
Anti-Tumour Drug More Potent With Light-Directed Delivery
Date:8/19/2009

OSLO, August 19 /PRNewswire/ --

- PCI Biotech's Light-Activated Drug Delivery System Combines With Tumour-Targeting Drugs to Halt Tumour Growth at Low Doses

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows.

Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

The researchers tested the approach on mice with human non-pigmented melanoma skin cancer grafts, using a drug consisting of a very potent toxin fused to an antibody fragment that recognizes a protein commonly found on the cancer cells, but not on normal cells. This allowed them to target the tumour cells specifically. Whilst drug therapy alone did not significantly slow growth of the tumours, using PCI to enhance the delivery process substantially improved the results.

Thus, in mice treated with both PCI and the tumour-targeting drug, half of the animals did not reach the defined end point for tumour growth, even by the end of the study (after 110 days). By contrast, all the mice receiving the drug alone had reached the endpoint after just 40 days, which was not significantly different from what was seen in untreated control animals. There were also no adverse effects on the mice, indicating that PCI technology can allow the use of drug doses so low that unwanted side effects in humans could be substantially reduced.

The study, by researchers at the Norwegian Radium Hospital in Oslo, Norway, and the M.D. Anderson Cancer Center in Houston, Texas, is published in the journal PLoS ONE.

Lead author of the study, Dr. Pal K. Selbo, comments: "In this study we have used an advanced biotechnological drug that consists of a protein toxin fused to a cancer-targeting moiety. The combination of the tumour targeting by the antibody and the light-directed drug delivery achieved by PCI gives extraordinarily specific therapy, effectively combining two different principles for specifically targeting the tumour cells. The increased delivery efficiency offered by the PCI technology makes it possible to achieve very good therapeutic effects with drug doses substantially lower than what is necessary without the help of PCI. The study demonstrates the excellent effect of the PCI technology with a very promising class of anticancer drugs, and could pave the way for the efficient and safe use of such drugs in humans."

Per Walday, CEO of PCI Biotech, adds: "This study further demonstrates the potential of the PCI technology in combination with important new classes of therapies. These results clearly demonstrate that PCI as a modality may greatly improve the efficacy of cell-targeted therapeutic agents. Our main priority going forward is to move the PCI technology into the clinic, to prove its safety and efficacy in man."

For more information visit: http://www.pcibiotech.com


'/>"/>
SOURCE PCI Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
5. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
6. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since ... ligament in her left knee. Lady’s owner Hannah sought the help of Dr Jeff ... surgeon, to repair her cruciate ligament and help with the pain of Lady’s arthritis. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... May 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2016. The cash dividend of ... 29, 2016 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):